Coronary/Structural Heart

ZOLL Launches Next Generation MCT Solution, Shown to Improve Patient Management Decisions in Largest Ever MCT Trial

The ZOLL Arrhythmia Management System (AMS) mobile cardiac telemetry (MCT) solution adds biometric data to traditional MCT data, helping physicians make more informed treatment plans CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced the launch of the ZOLL Arrhythmia Management […]

Tampa General Hospital and USF Health are First in Florida and Second in the U.S. to Replace a Tricuspid Valve… (cont’d)

Tampa General Hospital and USF Health are First in Florida and Second in the U.S. to Replace a Tricuspid Valve in the Heart Through a Minimally Invasive Procedure Using Transcatheter Bicaval Implants (TricValve) TAMPA, Fla., March 18, 2022 /PRNewswire/ — Tampa General Hospital (TGH) and USF Health Morsani College of Medicine Interventional Cardiologists reached multiple milestones […]

Cardiovascular Systems, Inc. Announces First In-Human Experience With Company’s Propel™ Percutaneous Ventricular Assist Device

ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the first in-human experience with Propel™, its first-generation percutaneous ventricular assist device (pVAD), offering hemodynamic support for patients undergoing high-risk […]

Lark Health Builds AI-Driven Heart Health Program

New Program Will Provide Real-Time Coaching to Support the Prevention and Management of Atherosclerotic Cardiovascular Disease and Coronary Artery Disease  MOUNTAIN VIEW, Calif., March 16, 2022 /PRNewswire/ — Lark Health today announced the development of a novel AI-driven program for the prevention and management of atherosclerotic cardiovascular disease (ASCVD) and coronary artery disease (CAD) […]

CareDx Brings Together Leading Transplant Experts to Share Latest Advancements in the Field of Xenotransplantation

SOUTH SAN FRANCISCO, Calif., March 16, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will hold a virtual “Xenotransplantation Innovation Day” featuring a […]

Vivasure Medical Announces First Patient Treated in U.S. Early Feasibility Study Evaluating PerQseal+

Study is the first in the U.S. to evaluate the company’s fully absorbable, patch-based percutaneous closure device for large-bore vessels in transcatheter aortic valve replacement GALWAY, Ireland–(BUSINESS WIRE)–Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the first patient was treated in a […]

Cardiawave Announces the Success of Its Clinical Trial to Treat Aortic Stenosis Using VALVOSOFT®, Its Disruptive, Non-Invasive, Ultrasound Treatment

The trial with VALVOSOFT® its disruptive, non-invasive, ultrasound treatment was proven to: be safe and feasible provide a sustained repair of the aortic valve improve quality of life of the 34 patients treated PARIS–(BUSINESS WIRE)–Cardiawave SA, a deeptech medical device company that has developed VALVOSOFT® a revolutionary non-invasive medical device to […]

Artivion Publishes Inaugural Corporate Responsibility Report

ATLANTA, March 14, 2022 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today published its inaugural Corporate Responsibility Report detailing the company’s Environmental, Social, and Governance (ESG) initiatives. Artivion’s 2022 Corporate Responsibility Report details several of the company’s ESG efforts, including: Environmental initiatives to drive sustainability and limit […]

Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock

On track for top-line data in April 2022 WARRINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has successfully completed enrollment in its phase 2 study of istaroxime […]